Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
2.5
Journals
Applied Sciences
Special Issues
Nuclear Medicine and Radiotherapy in Cancer Treatment
applsci-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Applied Sciences Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Nuclear Medicine and Radiotherapy in Cancer Treatment

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 1952

Special Issue Editors

Dr. Pedro Costa

E-Mail Website
Guest Editor
Nuclear Medicine Department, ESS - Polytechnic of Porto, 4200-072 Porto, Portugal
Interests: nuclear medicine; radiopharmacy; radionuclide production
Special Issues, Collections and Topics in MDPI journals
Dr. Ana Cravo Sá

E-Mail Website
Guest Editor Assistant
Department of Radiotherapy, ESS - Polytechnic University of Porto, 4200-072 Porto, Portugal
Interests: radiotherapy; dosimetry

Special Issue Information

Dear Colleagues,

In tackling the global health challenge of cancer, this Special Issue offers a critical exploration of innovative solutions. As technology assumes an increasingly pivotal role in modern medicine, the convergence of nuclear and radiation physics with oncology presents boundless potential. Radiation therapy, a cornerstone in cancer treatment, provides precise and effective means to combat tumors and alleviate patient suffering. On the other hand, nuclear medicine's versatile applications, spanning from precise imaging for diagnosis, planning, and follow-up, to targeted therapies using radiopharmaceuticals, have revolutionized cancer care, ushering in personalized treatment paradigms.

This Special Issue serves as a platform to delve into recent advancements and pioneering techniques in both domains. We welcome original contributions that probe into the development of cutting-edge methodologies for accurate diagnosis, treatment planning, and/or follow-up, alongside optimized approaches for radiation therapy-related dosimetry and technical enhancements in therapy delivery.

Let us collectively propel the frontiers of nuclear medicine and radiotherapy, striving towards heightened efficacy, diminished toxicity, and enhanced outcomes in cancer treatment.

Dr. Pedro Costa
Guest Editor

Dr. Ana Cravo Sá
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer treatment
  • dosimetry
  • nuclear medicine
  • PET
  • radioisotope therapy
  • radiotherapy
  • treatment planning

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1447 KiB  
Article
Development of Novel Nomograms to Predict 5- and 7-Year Biochemical-Recurrence-Free Survival in High-Risk Prostate Cancer Patients After Carbon-Ion Radiotherapy and Androgen Deprivation Therapy
by Takanobu Utsumi, Hiroyoshi Suzuki, Masaru Wakatsuki, Kana Kobayashi, Atsushi Okato, Mio Nakajima, Shuri Aoki, Taisuke Sumiya, Tomohiko Ichikawa, Koichiro Akakura, Hiroshi Tsuji, Shigeru Yamada and Hitoshi Ishikawa
Appl. Sci. 2025, 15(2), 804; https://doi.org/10.3390/app15020804 - 15 Jan 2025
Viewed by 811
Abstract
Background: The aim of this study was to develop nomograms predicting 5- and 7-year biochemical-recurrence (BCR)-free survival in high-risk prostate cancer (PCa) patients treated with carbon-ion radiotherapy (CIRT) and androgen deprivation therapy (ADT). Methods: We retrospectively evaluated 785 high-risk PCa patients treated with [...] Read more.
Background: The aim of this study was to develop nomograms predicting 5- and 7-year biochemical-recurrence (BCR)-free survival in high-risk prostate cancer (PCa) patients treated with carbon-ion radiotherapy (CIRT) and androgen deprivation therapy (ADT). Methods: We retrospectively evaluated 785 high-risk PCa patients treated with CIRT and ADT. Based on the least absolute shrinkage and selection operator model, two nomograms predicting 5- and 7-year BCR-free survival were developed and internally validated. The ability of each nomogram to predict BCR-free survival was determined by calculating the area under the survival curve (AUC). Results: The 5- and 7-year BCR-free survival rates were 92.1% and 89.3%, respectively. Age, prostate-specific antigen level, clinical T stage, and Gleason score were incorporated into the nomogram predicting 5-year BCR-free survival. In addition to these variables, the percentage of positive biopsy cores was also added to the nomogram predicting 7-year BCR-free survival. The AUC value of each nomogram showed suboptimal-to-good discrimination. Conclusions: We developed the first nomograms accurately predicting BCR-free survival in high-risk PCa patients treated with CIRT and ADT. These nomograms will enable adequate understanding and explanation of BCR-free survival to patients when clinicians use them. Full article
(This article belongs to the Special Issue Nuclear Medicine and Radiotherapy in Cancer Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop